# Immunomodulator Agents for Systemic Inflammatory Disease

**LENGTH OF AUTHORIZATIONS**: Dependent on diagnosis

**PRIOR AUTHORIZATION CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to all medications not requiring prior approval

- Contraindication to or drug-to-drug interaction with medications not requiring prior approval.

- History of unacceptable/toxic side effects to medications not requiring prior approval **All products in this class require Clinical Prior Authorization**:

- No current infection; and

- Prior first-generation therapy appropriate for diagnosis; and

- Diagnosis of one of the following: 365 days approval o Rheumatoid Arthritis o Plaque Psoriasis o Psoriatic Arthritis

-   Polyarticular Juvenile Idiopathic Arthritis
-   Crohn's Disease o Ankylosing Spondylitis o Psoriasis o Uveitis
-   Cryopyrin-Associated Periodic Syndrome
-   Giant Cell Arteritis o Hidradenitis Suppurativa

    - Diagnosis of Moderate to Severe Ulcerative Colitis (UC) (Humira, Simponi, and Xeljanz only): initial approval 56 days, reapprovals 365 days

    Humira may be approved if there is an inadequate clinical response to at least 90 days of therapy with both 5-ASA and immunosuppressants.

    Initial approval for Humira will be for 56 days. If clinical response is not seen in 56 days, further therapy with TNF inhibitors will not be approved. If there is an initial clinical response to Humira after 56 days of therapy, but no improvement in the progression of ulcerative colitis symptoms after 180 days, Simponi or Xeljanz may be approved.

-   Quantity limits for UC diagnosis:

    Humira – 7 pens/syringes during the first 30 days, then 2 pens/syringes per 30 days

    Simponi – 3 pens/syringes during the first 30 days, then 1 pen/syringe per 30 days Xeljanz – 60 pills per 30 days

**STEP THERAPY:**

1\. For a drug requiring step therapy, there must have been inadequate clinical response to a preferred alternative, including a trial of no less than 30 days of at least one preferred TNF inhibitor.

**ADDITIONAL INFORMATION**

The requested non-preferred medication may be approved if the following is true:

- If there has been a therapeutic failure to no less than a 90-day trial of at least two preferred medications

- For patients with a diagnosis of moderate to severe plaque psoriasis receiving phototherapy, initial authorization for Humira or Enbrel will only be approved if there is inadequate clinical response to at least 90 days of phototherapy.
